Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment
The drug, sold under the name Mavyret, can cure all six genetic types of the liver disease in eight weeks at a cost of $26,400, well below other options.
Drugs
1,101-1,120 of 1,318 results
-
-
Do Pharma’s Claims On Drug Prices Pass The Smell Test? We Found 5 Stinkers.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
By Jay Hancock -
Absent Federal Action, States Take The Lead On Curbing Drug Costs
Congress has yet to take substantive action on this growing consumer concern, but a number of states are flexing their cost-control muscle.
-
Out-Of-Pocket Costs Often Keep Pricey New Cholesterol Drugs Out Of Reach, Study Finds
Research published this week by JAMA Cardiology analyzed pharmacy claims data related to a new class of cholesterol-lowering drugs.
-
Right After Trump Blamed High Drug Prices On Campaign Cash, Drugmakers Gave More
At a political rally in March, President Donald Trump said drug prices are “outrageous” and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
By Sydney Lupkin and Elizabeth Lucas -
News Analysis
Everyone Says We Must Control Exorbitant Drug Prices. So, Why Don’t We?
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
By Jay Hancock -
High On Drugs? Anthem Cites Soaring Drug Costs To Justify 35% Rate Hike in California
The company’s drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
By Chad Terhune -
The Orphan Drug Machine
Without Price Breaks, Rural Hospitals Struggle To Stock Costly, Lifesaving Drugs
A federal drug program blocks rural hospitals from getting discounts on rare-disease drugs, forcing staff to cut back on supplies of lifesaving medicines.
-
The Orphan Drug Machine
FDA Moves To Guard Against Abuse Of ‘Orphan Drug’ Program
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
-
Meningitis B Vaccine’s High Price Poses A Health Care Conundrum For College-Bound
This immunization may mark a shift among some vaccine makers to higher-priced, “niche” preventives that protect against very specific and sometimes rare illnesses.
-
St. Kitts Launches Probe Of Herpes Vaccine Tests On U.S. Patients
After a Kaiser Health News report on an offshore herpes vaccine trial that skirted FDA regulations, St. Kitts and Nevis officials claim they had no knowledge of the testing. An investigation is underway.
-
Pioneering Cancer Gene Therapy Gets Green Light — And $475,000 Price Tag
The USA's first approved gene therapy — to be used to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment.
By Liz Szabo -
Facebook Live: The Prescription Drug Pricing Pipeline
In this Facebook Live, KHN’s Julie Appleby talks with Stephanie Stapleton and answers readers’ questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
-
Offshore Human Testing Of Herpes Vaccine Stokes Debate Over U.S. Safety Rules
Prominent businessmen and an American university supported offshore testing of an experimental vaccine.
-
‘Breakthrough’ Leukemia Drug Also Portends ‘Quantum Leap’ In Cost
A genetically altered cancer drug, based on CAR T-cell therapies, could be a big success with leukemia patients but at a staggering cost.
By Liz Szabo -
Dying At Home In An Opioid Crisis: Hospices Grapple With Stolen Meds
As more patients receive hospice care at home, some of the powerful, addictive drugs they’re prescribed are ending up in the wrong hands.
-
Podcast: ‘What The Health?’ Why Is It So Difficult To Control Drug Prices?
In this episode of “What the Health?” Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act’s marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
-
Climbing Cost Of Decades-Old Drugs Threatens To Break Medicaid Bank
Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
-
Hospitals Slashed Use Of Two Heart Drugs After Huge Price Hikes
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.
-
Taking A U-Turn On Benefits, Big Employers Vow To Continue Offering Health Insurance
Three years ago, only about a quarter of the nation’s large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
By Jay Hancock